BioCentury
ARTICLE | Clinical News

Seek Ltd., ValiRx preclinical data

September 22, 2014 7:00 AM UTC

In an in vivo model of NSCLC, VAL401 for 6 weeks led to at least a 50% reduction in tumor growth rate. ValiRx plans to report preclinical toxicology data for VAL401 by year end. Earlier this year, Val...